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Colorectal cancer (CRC) is one of the most common forms of cancer worldwide and familial adenomatous
polyposis (FAP) accounts for approximately 1% of all CRCs. Adenomatous polyposis syndromes can be divided into;
familial adenomatous polyposis (FAP) – classic FAP and attenuated familial adenomatous polyposis (AFAP), MUTYH-
associated polyposis (MAP), NTHL1-associated polyposis (NAP) and polymerase proofreading-associated polyposis
(PPAP). The polyposis syndromes genetics and clinical manifestation of disease varies and cases with clinical
diagnosis of FAP might molecularly show a different diagnosis.
This review examines different aspects of the adenomatous polyposis syndromes genetics and clinical manifestation of
disease; in addition the genotype-phenotype and modifier alleles of FAP will be discussed. New technology has made
it possible to diagnose some of the APC mutation negative patients into their respective syndromes. There still remain
many molecularly undiagnosed adenomatous polyposis patients indicating that there remain causative genes to be
discovered and with today’s technology these are expected to be identified in the near future. The knowledge about
the role of modifier alleles in FAP will contribute to improved pre-symptomatic diagnosis and treatment.
New novel mutations will continually be discovered in genes already associated with disease and new genes
will be discovered that are associated with adenomatous polyposis. The search for modifier alleles in FAP
should be made a priority.
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Background
Colorectal cancer (CRC) is one of the most common form
of cancer worldwide [1]. CRC development is considered
to be a result of a combination of genetic and environ-
mental factors and it is estimated that up to 35% of all
CRCs are associated with a genetic predisposition [2]. Fa-
milial adenomatous polyposis (FAP) accounts for approxi-
mately 1% of all CRCs [3] and is an autosomal dominantly
inherited condition where affected individuals develop
hundreds to thousands of adenomas (polyposis) through-
out the colon and rectum at unusually young ages. The
disease is due to mutations in the adenomatous polyposis
coli (APC) gene. If left untreated (if the colon is not re-
moved), one or more of these adenomas invariably be-
come malignant with almost 100% penetrance. Although
prophylactic surgery significantly reduces the mortality as-
sociated with FAP, extra-colonic manifestations of the dis-
ease are now more clinically relevant, most notably
desmoid tumours, which are hard to treat and a major
cause of death [4, 5]. Attenuated FAP (AFAP) is a milder
form of classic FAP with less polyps (<100) and a later age
of polyp/cancer onset.
Herein an update on the genetic basis of FAP and
other adenomatous polyposis syndromes (MAP, NAP
and PPAP) is discussed. This review focuses on the gen-
etics of FAP, the genetic phenotypes of the disease
(genotype-phenotype correlations) and studies on modi-
fier alleles. It also gives an update on other adenomatous
polyposis syndromes. Recent findings are highlighted
and gaps are identified in current literature, and consid-
eration is give as to how these may be addressed through
genomic approaches. A summary of the different aden-
omatous polyposis syndromes is shown in Table 1.
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Familial Adenomatous Polyposis (FAP) genetics
FAP is a result of germline mutations in APC [6, 7].
APC is a tumour suppressor gene that plays a cen-
tral role in the Wnt signalling pathway. A detailed
review of APC structure and function has been pub-
lished by Half et al. [8]. In brief, APC is located on
locus 5q21-22, consists of 15 coding exons (number
of exons have increased to 18 after the identification
of two promoter regions of APC [9]) and is 8532 bp
in size which translates to a protein comprising 2843
amino acids [10]. Somatic mutations in APC is also
a key molecular event in sporadic colorectal cancer
present in about 80% of patients [10]. Two codons
(1061 and 1309) are mutational hot-spots and ac-
count for 11 and 17% of all germline mutations, re-
spectively [11] and are common sites of somatic
change in sporadic CRC. But in a number of patients
no underlying germline mutation can be identified
[12, 13].
APC plays a central role in the Wnt-signalling path-
way, especially in regards to the degradation of β-catenin
within the cell cytoplasm. If APC is mutated, the β-
catenin-Tcf complex is not suppressed and leads to con-
stitutive activation of several genes and oncogenes con-
trolling cell growth and division [10]. Mutations in APC
affect the ability of the cell to maintain normal growth
and function, which results in cell overgrowth/adenoma
formation.
About 25% of people with FAP do not have any fam-
ily history of disease and harbour a de novo mutation
in APC without any clinical or genetic evidence of FAP
in the family [14–16]. One study suggests that a 5 bp
deletion of codon 1309 (c.3927_3931del) is over-
represented in patients with a suspected de novo muta-
tions (29%) and in proven de novo mutation carriers
(45%) [17], supporting the view of codon 1309 as a hot-
spot for mutations.
New methods that can screen genomic loci at great
depths are revealing that patients that were thought
to be APC mutation negative have pathogenic germ-
line heterozygous APC mutations [18], APC promoter
mutations [9], deep intronic mutations [19], complex
genomic rearrangements [20], somatic mutations or
APC mutation mosaicism [12, 21–23].
Table 1 Summary of adenomatous polyposis syndrome genetics, inheritance and clinical manifestation




FAP Germline APC mutations Autosomal
dominant
100–1000s colorectal polyps which manifests at age; early
childhood-mid 30s (typically 16) and rapidly increasing. Almost
100% risk of CRC if left untreated.
Treatment recommendations, colectomy after adenomas emerges.
Associated with adenomatous polyps colon, CRC, fundic gland
polyps, adenomatous polyps in the duodenum and periampullary
region, extra intestinal lesions (fibromas, lipomas, sebaceous and
epidermoid cysts = Gardner syndrome), desmoid tumours (benign
soft-tissue tumours), congenital hypertrophy of the retinal pigment
epithelium (CHRPE), and cancers of the brain (medulloblastoma =





AFAP Germline APC mutations Autosomal
dominant
<100 colorectal polyps (typically 30) at age typically between 40
and 70 years (average 55). Estimated 70% CRC risk by age
80 years.
Treatment recommendations, colectomy may be necessary but for
some polyps are limited enough in number that surveillance of
colon is sufficient.
Associated with adenomatous polyps of the colon, CRC, upper
gastrointestinal polyps, duodenal and gastric adenomas and
fundic glad polyps. In addition, hepatoblastoma, gastric and breast
adenocarcinoma have been documented.
MUTYH associated
polyposis




Usually < 100 polyps at average age of mid-50s and give a high
risk of CRC.









Polyp number unknown as it is a recently discovered association
but an extended spectrum of cancer diagnosis has been observed
(CRC, endometrium, duodenum, skin, breast, pancreatic and
others).








Polyp number unknown, also recently discovered.
Associated with multi-tumour phenotypes like colon/pancreas/
ovaries/small intestine and colon/ovarian/endometrial/brain.
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Classic FAP
Classic FAP (OMIM #175100) refers to patients who are
diagnosed with FAP due to the development of more
than 100 adenomatous colorectal polyps from early
childhood (typically at age 16) who harbour an APC
germline mutation. On average, cancer develops a dec-
ade after the appearance of adenomas and if the colon is
left untreated most patients develop CRC by 40 years of
age [8]. Other gastrointestinal manifestations include
fundic gland polyps (which occurs in approximately 90%
of FAP patients and are mostly benign [24]), adenoma-
tous polyps in the duodenum and periampullary region
(lifetime risk has been reported to reach 100% [25, 26]),
and small bowel adenomas [8]. Extra-colonic manifesta-
tions are common but rarely malignant and include [8];
desmoid tumours (benign soft-tissue tumours that can
be fatal due to progressive invasion into surrounding tis-
sues [5, 27]), cutaneous lesions such as fibromas, lip-
omas, sebaceous and epidermoid cysts (present in
Gardner syndrome [28], a phenotypic variant of FAP),
congenital hypertrophy of the retinal pigment epithelium
(CHRPE, which is a lesion causing discoloration in the
ocular fundus – low-grade adenocarcinoma has been de-
scribed in these lesions [29]), brain tumours (mainly me-
dulloblastoma, described in Turcot’s syndrome, another
phenotypic variant of FAP), hepatoblastoma, dental ab-
normalities, cancer of the pancreas, thyroid, gallbladder,
bile duct and adrenal glands [8, 30–32].
Attenuated familial adenomatous polyposis (AFAP)
AFAP is a phenotypic variant of FAP; patients develop
less than 100 polyps, delayed polyp growth and later age
of cancer onset. Germline APC mutations are also
present in these patients, which are mainly observed in
three sections of the gene (first 5 exons, exon 9 and in
the distal 3′end of APC) [33]. Mean age of polyp diagno-
sis in AFAP patients is variable but on average in fourth
to fifth decade of life, with cancer developing 10–15
years later [8, 34]. Screening is suggested to start late
teens to mid-20s [34]. As with FAP the most common
extra-colonic manifestations are upper gastrointestinal
polyps, duodenal and gastric adenomas and fundic gland
polyps [33]. Extra-colonic manifestations in AFAP are
rare but hepatoblastoma, gastric and breast adenocarcin-
oma have been documented [8, 33].
FAP genotype-phenotype
In families with FAP, considerable variability in disease
expression is observed within and between families har-
bouring identical APC mutations [13, 35–37] and it has
been shown that the greater the number of colorectal
adenomas, the greater the risk of CRC [38]. It has been
demonstrated that there is significant variation with re-
spect to age of onset of intestinal symptoms and the
development of CRC, even in patients with the same
mutations [13]. Haplotype reconstruction from pedigrees
have revealed there is no evidence for a specific APC
haplotype associated with disease severity [39].
Genotype-phenotype correlations have been associated
with the location of germline mutations within APC that
are related to disease severity and the expression of
extra-colonic disease [40–42], see figures in Half et al.
[8] and Macrae [10]. Patients with mutations in the mu-
tation cluster region (MCR), located between codons
1286 and 1513 [43], have generally a worse prognosis
with earlier disease onset than those with mutations out-
side this region [44]. Germline mutations at codon 1309
is associated with most severe disease [45], while milder
forms with less than 100 adenomas and later ages of on-
set (AFAP) are associated with codons <157, 312–412
and >1595 [33, 41]. CHRPE has been associated with
mutations between codons 457 and 1444 and suscepti-
bility to desmoid tumours is correlated with mutations
between codons 1395 and 2000, with slight variability in
codon ranges between reports [8, 10, 46]. There is evi-
dence of large phenotypic variation among patients with
identical germline mutations [13], strongly suggesting
the existence of FAP modifier alleles.
FAP modifier alleles
The phenotypic variation of APCMin mouse model of
FAP reveal among different inbred strains the import-
ance of modifier alleles [47]. There is evidence to suggest
that these phenotypic differences are caused by segregat-
ing modifier alleles that impact adenoma number [47].
Several have been found in the min mouse model. The best
known modifier is possibly Mom1 (modifier of Min 1),
which is semi-dominant - each copy affects tumour multi-
plicity by a factor of approximately 2 [47]. Pla2g2a (found
at the same region as Mom1) has also been shown to affect
the net growth rate of adjacent tumours [48]. The exact
mechanism by which it influences tumorigenesis remains
unresolved [47] and the effort of linking PLA2G2A to FAP
in humans has failed [49, 50], illustrating the difficult task
of searching for modifier alleles in FAP. Many different
genetic modifiers of the Apc knockout mouse models have
been found, affecting karyotypic stability, DNA mutation
rate, recombination rates, differentiation, DNA methylation,
stromal regulation, cell growth and proliferation (reviewed
in [47, 51]). There are claims that mouse models are essen-
tial in identifying modifiers of human disease and by using
an Apc (Min/+) model have identified seven genes that are
the most likely candidates for the Mom5 modifier [52]. Re-
cently it has been reported that a new Xenopus tumour
model might be especially useful for identifying or charac-
terising modifier genes associated with APC mediated
tumour formation [53].
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Genome wide association studies (GWASs) have iden-
tified approximately 40 CRC susceptibility loci, where
each loci gives a small increased risk of CRC [54]. The
risk associated with each variant is too small on their
own for translation to testing in clinical practice but the
development of algorithms estimating cumulative risk
are expected to lead to clinical application [54]. Two of
these SNPs have been associated with Lynch syndrome
[55, 56] and recently the same SNPs (rs16892766 and
rs3802842) have been associated with adenoma number
in APC mutation carriers causing a more sever FAP
phenotype [57].
Several studies suggest that low-penetrant susceptibility
genes may play an important role in the development of
sporadic CRC [58–63]. There is evidence to show that the
variation in FAP severity (which have been shown to be
independent of APC mutations and most likely the action
of modifier alleles), is expected to result in different rates
of adenoma number rather than differences in tumour
progression [64]. Modifier genes can influence individual
susceptibility to cancer by enhancing or suppressing dis-
ease initiation, growth and/or progression. The pattern of
intra-familial variation in colonic FAP severity is consist-
ent with the action of modifier genes [39, 64–66]. As de-
scribed above there is plenty of evidence from animal
models for the existence of FAP modifiers and knowledge
of modifier genes will contribute to better prophylactic
measures for FAP patients [67]. It is important that the
search for modifier genes/alleles continues.
Other adenomatous polyposis syndromes
Some of the recently discovered adenomatous polyposis
syndromes are recessively inherited and present a diagnos-
tic challenge. Individually, the other polyposis syndromes
are very rare and may show overlapping phenotypes.
MUTYH-associated polyposis (MAP)
MAP (OMIM #608456) is an autosomal recessive dis-
ease caused by biallelic mutations in the base excision
repair gene MUTYH. MUTYH is involved in base exci-
sion repair and is necessary in the amelioration of react-
ive oxygen species DNA damage prior to cell division
[68]. In a recent study, 23% of APC mutation negative
samples (FAP samples screened for APC mutations)
were found to harbour pathogenic mutations in MUTYH
[69]. Patients usually present with <100 colorectal polyps
at an average age of disease diagnosis at around 50 years
of age (which is similar to AFAP) and a high risk of CRC
[69, 70]. The age of onset of polyposis has been shown
to be significantly delayed for biallelic MUTYH carriers
compared to APC mutation carriers [69]. MAP has been
associated with malignancies of the duodenum, ovaries,
urinary bladder and skin—occasionally resembling the
phenotype of LS [71]. In a recent report describing
extra-colonic disease, biallelic carriers are at high risk of
urinary bladder and ovarian cancer, while there is some
evidence that monoallelic carriers are at risk of gastric,
hepatobiliary, endometrial and breast cancer [72]. No in-
creased risk of other extra-colonic cancers associated
with FAP was observed in this study [72].
NTHL1-associated polyposis (NAP)
A recently described autosomal recessive polyposis con-
dition has been named NAP (OMIM #616415). Patients
have germline homozygous or compound heterozygous
mutations in the base excision repair gene NTHL1 [73].
Due to its recent discovery the clinical manifestation is
not set, but it points towards an extended spectrum of
cancer diagnosis in these patients; endometrial, duo-
denal, skin (basal cell carcinoma) and others [74]. Given
such disease heterogeneity, Dutch researchers suggest it
is a novel cancer syndrome. This is supported by Canad-
ian researchers who also identified biallelic NTHL1 mu-
tations in a woman with multiple primary tumours [75].
Polymerase proofreading-associated polyposis (PPAP)
PPAP is associated with mono- and biallelic mutations
in the genes POLE and POLD1 [76], both genes a part of
the mismatch repair (MMR) pathway. PPAP is in an
autosomal dominantly inherited CRC predisposition
[77]. Variants in POLE and POLD1 are known to in-
crease the somatic mutation rate in tumours [78],
thereby increasing the risk of tumour development. The
somatic mutation landscape can display great diversity
[79], which could be a reason for the differences ob-
served in the location of primary tumours between pa-
tients. Both POLE and POLD1 have been associated with
an increased risk of endometrial cancer [76, 80]. POLD1
has been associated with breast and brain tumours in
addition to CRC and endometrial cancer [81]. Multi-
tumour phenotypes such as colon/pancreas/ovaries/
small intestine [82] and colon/ovarian/endometrial/brain
[80] have been seen in POLE mutation carriers. In
addition, POLE has been linked to an early onset cancer
case raising the question whether this specific POLE mu-
tation may confer a more severe phenotype than previ-
ously reported POLE/POLD1 mutations [83].
Conclusions
Genetic testing has rapidly grown in the last few years
with the advancement of next-generation sequencing
technologies. Targeted testing of all polyposis patients
with a gene-panel can now be performed at reasonable
cost such that targeted screening or prophylactic surgery
can be offered to patients with a molecular diagnosis of
polyposis.
In 2009 Half et al. [8] identified unresolved questions
regarding FAP, one being that there are many FAP
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patients who do not get a molecular diagnosis. Since 2009,
three additional genes have been associated with aden-
omatous polyposis, one being NTHL1 which has been
classified as NAP, and POLE and POLD1 which has been
classified as PPAP.
New novel mutations will continually be discovered in
genes already associated with disease and new genes will
be discovered that are associated with adenomatous
polyposis. Exome sequencing has already been used to
identify new candidate genes; PIEZ01 and ZSWiM7 [84],
which are currently subject to further investigation.
A recent study has found that gene expression of APC
was reduced in FAP patients without germline APC muta-
tions [85]. An explanation may lie in differential epigenetic
factors that contribute to the lack of gene expression in
these patients, maybe more focus should be placed on un-
derstanding the role of epigenetics in polyposis syndromes.
There remain a high proportion of APC mutation nega-
tive patients even after extensive searches for new causa-
tive genes. The question remains, have we just missed
them, or is it that these patients harbour rare alleles that
await discovery. Diagnostics laboratories around the world
are spending considerable amounts of time designing
gene-panels to test for all adenomatous polyposis syn-
dromes using new sequencing technology such that in the
near future the number of APC mutation negative patients
is expected to significantly decrease. Until then, re-testing
“old” APC mutation negative patients for additional genes
that have already been identified should be of special
interest.
Acknowledgment
Thank you to Professor Rodney J. Scott for helping with the editing of the
final draft of the manuscript.
Funding
This work was supported by the Liaison Committee between the Central
Norway Regional Health Authority (RHA) and the Norwegian University of
Science and Technology (NTNU), Norway; Møre og Romsdal Hospital Trust,
Norway; and the Cancer Institute NSW, Australia.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or
analysed during the current study.
Author’s contributions
BTP has reviewed the literature and written the review.
Competing interests
The author declares that she has no competing interest.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Laboratory Medicine, Children’s and Women’s Health, Faculty
of Medicine and Health Sciences, Norwegian University of Science and
Technology, Trondheim 7491, Norway. 2Clinic for Medicine, Møre og
Romsdal Hospital Trust, Molde, Norway. 3School of Biomedical Sciences and
Pharmacy, Faculty of Health and Medicine, University of Newcastle,
Newcastle, NSW, Australia. 4Hunter Medical Research Institute, Newcastle,
NSW, Australia. 5Clinic for Medicine, Library, Molde Hospital, Parkvegen 84,
Molde 6407, Norway.
Received: 18 March 2016 Accepted: 7 March 2017
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;
65(1):5–29. doi:10.3322/caac.21254.
2. Davidson NO. Genetic testing in colorectal cancer: who, when, how and
why. Keio J Med. 2007;56(1):14–20.
3. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet.
2001;10(7):721–33.
4. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg.
1996;83(11):1494–504.
5. Sturt NJ, Clark SK. Current ideas in desmoid tumours. Fam Cancer. 2006;5(3):
275–85. doi:10.1007/s10689-005-5675-1. discussion 87–8.
6. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al.
Identification and characterization of the familial adenomatous polyposis
coli gene. Cell. 1991;66(3):589–600.
7. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al.
Identification of FAP locus genes from chromosome 5q21. Science. 1991;
253(5020):661–5.
8. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J
Rare Dis. 2009;4:22. doi:10.1186/1750-1172-4-22.
9. Rohlin A, Engwall Y, Fritzell K, Goransson K, Bergsten A, Einbeigi Z, et al.
Inactivation of promoter 1B of APC causes partial gene silencing: evidence
for a significant role of the promoter in regulation and causative of familial
adenomatous polyposis. Oncogene. 2011;30(50):4977–89. doi:10.1038/onc.
2011.201.
10. Macrae F, du Sart D, Nasioulas S. Familial adenomatous polyposis. Best Pract
Res Clin Gastroenterol. 2009;23(2):197–207. doi:10.1016/j.bpg.2009.02.010.
11. Jass JR. Colorectal polyposes: from phenotype to diagnosis. Pathol Res Pract.
2008;204(7):431–47. doi:10.1016/j.prp.2008.03.008.
12. Spier I, Drichel D, Kerick M, Kirfel J, Horpaopan S, Laner A et al. Low-level
APC mutational mosaicism is the underlying cause in a substantial fraction
of unexplained colorectal adenomatous polyposis cases. J Med Genet. 2015.
doi:10.1136/jmedgenet-2015-103468.
13. Friedl W, Caspari R, Sengteller M, Uhlhaas S, Lamberti C, Jungck M, et al. Can APC
mutation analysis contribute to therapeutic decisions in familial adenomatous
polyposis? Experience from 680 FAP families. Gut. 2001;48(4):515–21.
14. Gayther SA, Wells D, SenGupta SB, Chapman P, Neale K, Tsioupra K, et al.
Regionally clustered APC mutations are associated with a severe phenotype
and occur at a high frequency in new mutation cases of adenomatous
polyposis coli. Hum Mol Genet. 1994;3(1):53–6.
15. Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J. Familial adenomatous
polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat.
1994;3(2):121–5. doi:10.1002/humu.1380030206.
16. Zhang Y, Lu G, Hu Q, Wang X, Li C, Mao Y, et al. A de novo germline
mutation of APC for inheritable colon cancer in a Chinese family using
multigene next generation sequencing. Biochem Biophys Res Commun.
2014;447(3):503–7. doi:10.1016/j.bbrc.2014.04.014.
17. Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, et al.
Frequency and parental origin of de novo APC mutations in familial
adenomatous polyposis. Eur J Hum Genet. 2004;12(1):52–8. doi:10.1038/sj.
ejhg.5201088.
18. Out AA, van Minderhout IJ, van der Stoep N, van Bommel LS, Kluijt I, Aalfs
C, et al. High-resolution melting (HRM) re-analysis of a polyposis patients
cohort reveals previously undetected heterozygous and mosaic APC gene
mutations. Fam Cancer. 2015;14(2):247–57. doi:10.1007/s10689-015-9780-5.
19. Spier I, Horpaopan S, Vogt S, Uhlhaas S, Morak M, Stienen D, et al. Deep
intronic APC mutations explain a substantial proportion of patients with
familial or early-onset adenomatous polyposis. Hum Mutat. 2012;33(7):1045–
50. doi:10.1002/humu.22082.
Talseth-Palmer Hereditary Cancer in Clinical Practice  (2017) 15:5 Page 5 of 7
20. Charames GS, Ramyar L, Mitri A, Berk T, Cheng H, Jung J, et al. A large novel
deletion in the APC promoter region causes gene silencing and leads to
classical familial adenomatous polyposis in a Manitoba Mennonite kindred.
Hum Genet. 2008;124(5):535–41. doi:10.1007/s00439-008-0579-4.
21. Hes FJ, Nielsen M, Bik EC, Konvalinka D, Wijnen JT, Bakker E, et al. Somatic
APC mosaicism: an underestimated cause of polyposis coli. Gut. 2008;57(1):
71–6. doi:10.1136/gut.2006.117796.
22. Aretz S, Stienen D, Friedrichs N, Stemmler S, Uhlhaas S, Rahner N, et al.
Somatic APC mosaicism: a frequent cause of familial adenomatous
polyposis (FAP). Hum Mutat. 2007;28(10):985–92. doi:10.1002/humu.20549.
23. Yamaguchi K, Komura M, Yamaguchi R, Imoto S, Shimizu E, Kasuya S, et al.
Detection of APC mosaicism by next-generation sequencing in an FAP
patient. J Hum Genet. 2015;60(5):227–31. doi:10.1038/jhg.2015.14.
24. Bianchi LK, Burke CA, Bennett AE, Lopez R, Hasson H, Church JM. Fundic
gland polyp dysplasia is common in familial adenomatous polyposis. Clin
Gastroenterol Hepatol. 2008;6(2):180–5. doi:10.1016/j.cgh.2007.11.018.
25. Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, et al.
Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53(3):
381–6.
26. Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas
in 98 patients with familial adenomatous polyposis. Endoscopy. 1999;31(6):
412–6. doi:10.1055/s-1999-41.
27. Soravia C, Berk T, McLeod RS, Cohen Z. Desmoid disease in patients with
familial adenomatous polyposis. Dis Colon Rectum. 2000;43(3):363–9.
28. Juhn E, Khachemoune A. Gardner syndrome: skin manifestations, differential
diagnosis and management. Am J Clin Dermatol. 2010;11(2):117–22. doi:10.
2165/11311180-000000000-00000.
29. Shields JA, Shields CL, Eagle Jr RC, Singh AD. Adenocarcinoma arising from
congenital hypertrophy of retinal pigment epithelium. Arch Ophthalmol.
2001;119(4):597–602.
30. Nilbert M, Kristoffersson U, Ericsson M, Johannsson O, Rambech E, Mangell
P. Broad phenotypic spectrum in familial adenomatous polyposis; from early
onset and severe phenotypes to late onset of attenuated polyposis with
the first manifestation at age 72. BMC Med Genet. 2008;9:101. doi:10.1186/
1471-2350-9-101.
31. Boger C, Haag J, Egberts JH, Rocken C. Complex APC germline mutation
associated metaplasia and intraepithelial neoplasia (CAM-IEN) of the
gallbladder. Pathol Res Pract. 2016;212(1):54–8. doi:10.1016/j.prp.2015.11.010.
32. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J
Gastroenterol. 2006;101(2):385–98. doi:10.1111/j.1572-0241.2006.00375.x.
33. Knudsen AL, Bisgaard ML, Bulow S. Attenuated familial adenomatous
polyposis (AFAP). A review of the literature. Fam Cancer. 2003;2(1):43–55.
34. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al.
ACG clinical guideline: Genetic testing and management of hereditary
gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62.
doi:10.1038/ajg.2014.435. quiz 63.
35. Giardiello FM, Krush AJ, Petersen GM, Booker SV, Kerr M, Tong LL, et al.
Phenotypic variability of familial adenomatous polyposis in 11 unrelated families
with identical APC gene mutation. Gastroenterology. 1994;106(6):1542–7.
36. Brensinger JD, Laken SJ, Luce MC, Powell SM, Vance GH, Ahnen DJ, et al.
Variable phenotype of familial adenomatous polyposis in pedigrees with 3′
mutation in the APC gene. Gut. 1998;43(4):548–52.
37. Scott RJ, van der Luijt R, Spycher M, Mary JL, Muller A, Hoppeler T, et al.
Novel germline APC gene mutation in a large familial adenomatous
polyposis kindred displaying variable phenotypes. Gut. 1995;36(5):731–6.
38. Debinski HS, Love S, Spigelman AD, Phillips RK. Colorectal polyp counts and cancer
risk in familial adenomatous polyposis. Gastroenterology. 1996;110(4):1028–30.
39. Crabtree MD, Fletcher C, Churchman M, Hodgson SV, Neale K, Phillips RK,
et al. Analysis of candidate modifier loci for the severity of colonic familial
adenomatous polyposis, with evidence for the importance of the N-acetyl
transferases. Gut. 2004;53(2):271–6.
40. Lipton L, Tomlinson I. The genetics of FAP and FAP-like syndromes. Fam
Cancer. 2006;5(3):221–6. doi:10.1007/s10689-005-5673-3.
41. Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and
phenotype of familial adenomatous polyposis (FAP): a review of the
literature. Crit Rev Oncol Hematol. 2007;61(2):153–61. doi:10.1016/j.
critrevonc.2006.07.004.
42. Lynch HT, Watson P. AFAP: variety is the spice of life. Gut. 1998;43(4):451–2.
43. Cetta F, Dhamo A. Inherited multitumoral syndromes including
colorectal carcinoma. Surg Oncol. 2007;16 Suppl 1:S17–23. doi:10.1016/j.
suronc.2007.10.013.
44. Wachsmannova-Matelova L, Stevurkova V, Adamcikova Z, Holec V, Zajac V.
Different phenotype manifestation of familial adenomatous polyposis in
families with APC mutation at codon 1309. Neoplasma. 2009;56(6):486–9.
45. Houlston R, Crabtree M, Phillips R, Tomlinson I. Explaining differences in the
severity of familial adenomatous polyposis and the search for modifier
genes. Gut. 2001;48(1):1–5.
46. Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, et al. Multiple
approach to the exploration of genotype-phenotype correlations in familial
adenomatous polyposis. J Clin Oncol. 2003;21(9):1698–707. doi:10.1200/JCO.
2003.09.118.
47. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med
Biol. 2009;656:85–106.
48. Cormier RT, Dove WF. Dnmt1N/+ reduces the net growth rate and multiplicity
of intestinal adenomas in C57BL/6-multiple intestinal neoplasia (Min)/+ mice
independently of p53 but demonstrates strong synergy with the modifier of
Min 1(AKR) resistance allele. Cancer Res. 2000;60(14):3965–70.
49. Nimmrich I, Friedl W, Kruse R, Pietsch S, Hentsch S, Deuter R, et al. Loss of
the PLA2G2A gene in a sporadic colorectal tumor of a patient with a
PLA2G2A germline mutation and absence of PLA2G2A germline alterations
in patients with FAP. Hum Genet. 1997;100(3–4):345–9.
50. Tomlinson IP, Beck NE, Neale K, Bodmer WF. Variants at the secretory
phospholipase A2 (PLA2G2A) locus: analysis of associations with familial
adenomatous polyposis and sporadic colorectal tumours. Ann Hum Genet.
1996;60(Pt 5):369–76.
51. McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and
mutants. Pathol Res Pract. 2008;204(7):479–90. doi:10.1016/j.prp.2008.03.004.
52. Otterpohl KL, Gould KA. Genetic dissection of the Mom5 modifier locus and
evaluation of Mom5 candidate genes. Mamm Genome. 2015;26(5–6):235–
47. doi:10.1007/s00335-015-9567-x.
53. Van Nieuwenhuysen T, Naert T, Tran HT, Van Imschoot G, Geurs S, Sanders
E, et al. TALEN-mediated apc mutation in Xenopus tropicalis phenocopies
familial adenomatous polyposis. Oncoscience. 2015;2(5):555–66.
54. Short E, Thomas LE, Hurley J, Jose S, Sampson JR. Inherited predisposition to
colorectal cancer: towards a more complete picture. J Med Genet. 2015;
52(12):791–6. doi:10.1136/jmedgenet-2015-103298.
55. Talseth-Palmer BA, Brenne IS, Ashton KA, Evans TJ, McPhillips M,
Groombridge C, et al. Colorectal cancer susceptibility loci on chromosome
8q23.3 and 11q23.1 as modifiers for disease expression in lynch syndrome. J
Med Genet. 2011;48(4):279–84.
56. Wijnen JT, Brohet RM, van Eijk R, Jagmohan-Changur S, Middeldorp A, Tops
CM, et al. Chromosome 8q23.3 and 11q23.1 variants modify colorectal
cancer risk in Lynch syndrome. Gastroenterology. 2009;136(1):131–7.
57. Ghorbanoghli Z, Nieuwenhuis MH, Houwing-Duistermaat JJ, Jagmohan-
Changur S, Hes FJ, Tops CM et al. Colorectal cancer risk variants at 8q23.3
and 11q23.1 are associated with disease phenotype in APC mutation
carriers. Fam Cancer. 2016. doi:10.1007/s10689-016-9877-5.
58. Jaeger E, Webb E, Howarth K, Carvajal-Carmona L, Rowan A, Broderick
P, et al. Common genetic variants at the CRAC1 (HMPS) locus on
chromosome 15q13.3 influence colorectal cancer risk. Nat Genet. 2008;
40(1):26–8.
59. Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, et
al. Genome-wide association scan identifies a colorectal cancer susceptibility
locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet. 2008;
40(5):631–7.
60. Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman
AM, et al. A genome-wide association study identifies colorectal cancer
susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet. 2008;
40(5):623–30.
61. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A,
et al. A genome-wide association study shows that common alleles of
SMAD7 influence colorectal cancer risk. Nat Genet. 2007;39(11):1315–7.
62. Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, et al.
Meta-analysis of three genome-wide association studies identifies
susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.
33. Nat Genet. 2010;42(11):973–7. doi:10.1038/ng.670.
63. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S,
et al. Meta-analysis of genome-wide association data identifies four new
susceptibility loci for colorectal cancer. Nat Genet. 2008;40(12):1426–35. doi:
10.1038/ng.262.
64. Crabtree MD, Tomlinson IP, Talbot IC, Phillips RK. Variability in the severity of
colonic disease in familial adenomatous polyposis results from differences
Talseth-Palmer Hereditary Cancer in Clinical Practice  (2017) 15:5 Page 6 of 7
in tumour initiation rather than progression and depends relatively little on
patient age. Gut. 2001;49(4):540–3.
65. Crabtree MD, Tomlinson IP, Hodgson SV, Neale K, Phillips RK, Houlston RS.
Explaining variation in familial adenomatous polyposis: relationship
between genotype and phenotype and evidence for modifier genes. Gut.
2002;51(3):420–3.
66. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, et al.
Genetic identification of Mom-1, a major modifier locus affecting Min-
induced intestinal neoplasia in the mouse. Cell. 1993;75(4):631–9.
67. Ballhausen WG. Genetic testing for familial adenomatous polyposis. Ann N Y
Acad Sci. 2000;910:36–47. discussion −9.
68. Lucci-Cordisco E, Risio M, Venesio T, Genuardi M. The growing complexity
of the intestinal polyposis syndromes. Am J Med Genet A. 2013;161A(11):
2777–87. doi:10.1002/ajmg.a.36253.
69. Papp J, Kovacs ME, Matrai Z, Orosz E, Kasler M, Borresen-Dale AL, et al.
Contribution of APC and MUTYH mutations to familial adenomatous
polyposis susceptibility in Hungary. Fam Cancer. 2016;15(1):85–97. doi:10.
1007/s10689-015-9845-5.
70. Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical implications of
the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol.
2009;27(24):3975–80. doi:10.1200/JCO.2008.21.6853.
71. Morak M, Heidenreich B, Keller G, Hampel H, Laner A, de la Chapelle A, et al.
Biallelic MUTYH mutations can mimic Lynch syndrome. Eur J Hum Genet.
2014;22(11):1334–7. doi:10.1038/ejhg.2014.15.
72. Win AK, Reece JC, Dowty JG, Buchanan DD, Clendenning M, Rosty C, et al. Risk
of extracolonic cancers for people with biallelic and monoallelic mutations in
MUTYH. Int J Cancer. 2016;139(7):1557–63. doi:10.1002/ijc.30197.
73. Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, et al.
A germline homozygous mutation in the base-excision repair gene NTHL1
causes adenomatous polyposis and colorectal cancer. Nat Genet. 2015;47(6):
668–71. doi:10.1038/ng.3287.
74. Kuiper RP, Hoogerbrugge N. NTHL1 defines novel cancer syndrome.
Oncotarget. 2015;6(33):34069–70. 10.18632/oncotarget.5864.
75. Rivera B, Castellsague E, Bah I, van Kempen LC, Foulkes WD. Biallelic NTHL1
Mutations in a Woman with Multiple Primary Tumors. N Engl J Med. 2015;
373(20):1985–6. doi:10.1056/NEJMc1506878.
76. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al.
Germline mutations affecting the proofreading domains of POLE and
POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet.
2013;45(2):136–44. doi:10.1038/ng.2503.
77. Church JM. Polymerase proofreading-associated polyposis: a new,
dominantly inherited syndrome of hereditary colorectal cancer
predisposition. Dis Colon Rectum. 2014;57(3):396–7. doi:10.1097/DCR.
0000000000000084.
78. Heitzer E, Tomlinson I. Replicative DNA polymerase mutations in cancer.
Curr Opin Genet Dev. 2014;24:107–13. doi:10.1016/j.gde.2013.12.005.
79. Rashid M, Fischer A, Wilson CH, Tiffen J, Rust AG, Stevens P, et al. Adenoma
development in familial adenomatous polyposis and MUTYH-associated
polyposis: somatic landscape and driver genes. J Pathol. 2016;238(1):98–108.
doi:10.1002/path.4643.
80. Rohlin A, Zagoras T, Nilsson S, Lundstam U, Wahlstrom J, Hulten L, et al. A
mutation in POLE predisposing to a multi-tumour phenotype. Int J Oncol.
2014;45(1):77–81. doi:10.3892/ijo.2014.2410.
81. Nicolas E, Golemis EA, Arora S. POLD1: Central mediator of DNA replication
and repair, and implication in cancer and other pathologies. Gene. 2016;
590(1):128–41. doi:10.1016/j.gene.2016.06.031.
82. Hansen MF, Johansen J, Bjornevoll I, Sylvander AE, Steinsbekk KS, Saetrom P, et al.
A novel POLE mutation associated with cancers of colon, pancreas, ovaries and
small intestine. Fam Cancer. 2015;14(3):437–48. doi:10.1007/s10689-015-9803-2.
83. Wimmer K, Beilken A, Nustede R, Ripperger T, Lamottke B, Ure B, et al. A
novel germline POLE mutation causes an early onset cancer prone
syndrome mimicking constitutional mismatch repair deficiency. Fam Cancer.
2017;16(1):67–71. doi:10.1007/s10689-016-9925-1.
84. Spier I, Kerick M, Drichel D, Horpaopan S, Altmuller J, Laner A et al. Exome
sequencing identifies potential novel candidate genes in patients with
unexplained colorectal adenomatous polyposis. Fam Cancer. 2016. doi:10.
1007/s10689-016-9870-z.
85. Aceto GM, Fantini F, De Iure S, Di Nicola M, Palka G, Valanzano R, et al.
Correlation between mutations and mRNA expression of APC and MUTYH
genes: new insight into hereditary colorectal polyposis predisposition. J Exp
Clin Cancer Res. 2015;34:131. doi:10.1186/s13046-015-0244-4.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Talseth-Palmer Hereditary Cancer in Clinical Practice  (2017) 15:5 Page 7 of 7
